What's in Arcutis Biotherapeutics's pipeline?

Arcutis Biotherapeutics has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Arcutis Biotherapeutics's portfolio?

Top competitors by shared drug class: Amgen, Anacor Pharms Inc.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/arcutis.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Arcutis Biotherapeutics — Portfolio Competitive Intelligence Brief

Arcutis Biotherapeutics (ARQT) pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

ARQT (NASDAQ) 1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Daliresp	ROFLUMILAST	marketed	Phosphodiesterase 4 Inhibitor [EPC]	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Immunology	2011-01-01

Therapeutic area mix

Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Amgen · 1 shared drug class
Anacor Pharms Inc · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Arcutis Biotherapeutics:

Cite this brief

Drug Landscape (2026). Arcutis Biotherapeutics — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/arcutis. Accessed 2026-05-14.